iShares China Large-Cap ETF (FXI)

Key Updates

FXI declined 2.23% to $36.44 since the April 16 report, reversing four consecutive periods of gains and marking the first negative movement since late March. The pullback occurred despite minimal new negative catalysts, with only six news articles compared to 17 in the previous period. The decline appears to represent profit-taking following the sustained rally rather than fundamental deterioration, as institutional sentiment remains constructive with multiple asset managers projecting 10% upside by year-end and active funds maintaining benchmark-neutral positioning for the first time since 2022.

Current Trend

FXI trades at $36.44, down 4.83% year-to-date and experiencing near-term weakness with declines of 1.43% (1-day), 2.12% (5-day), and 2.23% since the last report. However, the 1-month performance of +3.11% demonstrates resilience following the March geopolitical shock, while the 6-month decline of 9.82% reflects the broader challenges facing Chinese equities. The ETF has established support near the $35.50-$36.00 range tested in early April and faces resistance at the $37.50 level reached mid-April. The current price action suggests consolidation within this range as markets digest the recent rally and await catalysts for the next directional move.

Investment Thesis

The investment thesis centers on Chinese large-cap equities trading at compelling valuations with a CSI 300 price-to-earnings ratio of 18 times—representing a 20% discount to the MSCI World Index—while positioned to benefit from structural shifts in AI adoption, healthcare innovation, and energy transition. China's demonstrated resilience during the Iran-driven oil shock, supported by seven months of oil stockpiles and the world's largest electric vehicle fleet, validates its role as portfolio ballast during geopolitical turbulence. The stabilization of property markets, accommodating regulatory policies, and expected 5-10% earnings growth provide fundamental support, while household savings yielding only 1.8% in bonds create conditions for equity reallocation. Major institutional investors including Eurizon SLJ Capital and Goldman Sachs have upgraded Chinese equities, targeting 10% appreciation by year-end with the CSI 300 reaching above 5,000-5,100 from current levels near 4,700.

Thesis Status

The investment thesis remains intact despite the 2.23% pullback, which appears tactical rather than structural. Key thesis components continue to strengthen: active long-only funds reached benchmark-neutral positioning for the first time since 2022, indicating normalization of institutional allocations; ChinaAMC, China's largest equity ETF provider, is aggressively integrating AI across its RMB 3.245 trillion ($464.5 billion) platform; and JPMorgan is pursuing regulatory approval for active ETFs in China as part of its strategy to double Asia-Pacific AUM to $600 billion. The recent decline does not alter the fundamental drivers of property market stabilization, attractive valuations, or AI investment acceleration. However, the thesis faces near-term headwinds from profit-taking after the March-April rally and the 6-month decline of 9.82% indicates sustained distribution pressure that requires resolution before sustained upside can materialize.

Key Drivers

AI investment acceleration continues as a primary growth driver, with portfolio manager Leo Fan arguing Chinese AI stocks are not in bubble territory and benefit from lower development costs compared to US counterparts, while major companies like Tencent and Alibaba only recently accelerated investments. ChinaAMC's integration of AI since 2017 through Microsoft Research Asia partnership demonstrates institutional commitment, with the firm generating 1.6 million views covering Nvidia GTC 2026 and applying AI-enhanced strategies across its operations. Property market stabilization provides fundamental support, with improving supply-demand dynamics and strong export profitability creating conditions for the CSI 300 to rise from approximately 4,700 to above 5,000. Market structure evolution is underway as JPMorgan pursues approval for actively managed ETFs beyond the current "enhanced index" limitation of 20% benchmark deviation, with full active management approval expected this year. Geopolitical resilience demonstrated during the Iran-Israel conflict, with the CSI300 declining only 4.6% versus deeper losses in India (over 10%), Japan, South Korea, and the S&P 500 (nearly 8%), validates China's defensive characteristics supported by seven months of oil stockpiles and diversified energy supply chains.

Technical Analysis

FXI established a trading range between $35.50-$37.50 following the March geopolitical shock, with the current price of $36.44 positioned in the middle of this consolidation zone. The ETF tested resistance at $37.27 on April 16 before pulling back 2.23%, suggesting profit-taking after the four-period rally that began in late March. Support remains at the $35.50-$36.00 level tested in early April, which coincides with the March recovery low. The 1-month gain of 3.11% demonstrates constructive momentum despite the recent pullback, while the 6-month decline of 9.82% indicates overhead supply that must be absorbed for sustained breakout above $37.50. The year-to-date decline of 4.83% positions FXI ahead of the MSCI China Index's 1% decline referenced in market commentary, suggesting relative strength within Chinese equities. Volume patterns and the reduction in news flow from 17 to 6 articles indicate consolidation rather than distribution, with the next catalyst likely determining whether FXI breaks above $37.50 resistance or retests $35.50 support.

Bull Case

• Institutional price targets of 10% upside by year-end from Eurizon SLJ Capital, with the CSI 300 expected to rise from approximately 4,700 to above 5,000, driven by stabilizing property markets, accommodating government policies, 5-10% earnings growth, and household savings yielding only 1.8% in bonds creating conditions for equity reallocation.
• AI value chain opportunity with lower development costs than US counterparts, as major companies like Tencent and Alibaba only recently accelerated AI investments, with successful funds allocating 18% to communication services and information technology across the AI value chain delivering 15% YTD returns versus MSCI China Index's 1% decline.
• Demonstrated geopolitical resilience with CSI300 declining only 4.6% during the Iran-Israel oil shock versus over 10% in India and nearly 8% in the S&P 500, supported by seven months of oil stockpiles, diversified energy supply from Russia and Central Asia, the world's largest electric vehicle fleet, and low inflation absorbing higher energy costs.
• Active fund positioning normalization with long-only funds reaching benchmark-neutral levels for the first time since 2022, indicating institutional reallocation after years of underweighting, while Goldman Sachs upgraded Chinese stocks citing resilience, renewable energy strength, and 20% valuation discount to MSCI World Index.
• Healthcare sector cost advantages with China's biopharmaceutical companies benefiting from lower drug development costs and rising outbound licensing deals, as evidenced by top-performing funds allocating 24% to healthcare and generating 15% YTD returns while the broader market declined 1%.

Bear Case

• Minimal YTD performance of 1.5% for Chinese stocks in 2026 despite 25% twelve-month gains, with FXI down 4.83% YTD and 9.82% over six months, indicating sustained distribution pressure and profit-taking that has overwhelmed fundamental improvements and institutional upgrades.
• Temporary correlation dynamics between stocks and bonds that may not persist once Middle East tensions ease, with analysts cautioning that the positive 90-day correlation driven by safe-haven demand could reverse, eliminating the defensive characteristics that attracted recent flows.
• Structural exclusion by ex-China funds holding approximately $17 billion in the iShares MSCI Emerging Markets ex China ETF alone, with investors maintaining these positions for non-performance reasons including personal values, legal restrictions in certain US states, and institutional preferences for independent China allocation decisions, creating persistent selling pressure.
• Regulatory uncertainty on active ETF approval with JPMorgan still awaiting Chinese securities authority approval for actively managed ETFs beyond the current 20% benchmark deviation limit, indicating that market structure improvements remain dependent on regulatory decisions with uncertain timing.
• Concentrated performance in select strategies with only 2% of peers matching ChinaAMC's 15% YTD returns, suggesting that broad market participation remains limited and gains are concentrated in specific AI, healthcare, and technology exposures rather than reflecting broad-based Chinese equity strength that would support sustained FXI appreciation.